Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The company expects to recognize out-licensing revenue progressively starting in 2026, with significant upfront payments from collaborations with Roche and Takeda [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [19][21] Financial Summary - Revenue projections for FY26 and FY27 have been raised to RMB 17.8 billion and RMB 20.5 billion, respectively, along with net profit forecasts of RMB 2.3 billion and RMB 3.5 billion [10][21] - The company’s selling expenses increased by 31% year-on-year to RMB 5.7 billion, while R&D expenses decreased by 2% to RMB 2.6 billion [3][15] - The report indicates a strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to drive further growth in 2026 [4][16]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]

Core Viewpoint - The company is expected to achieve strong revenue and profit growth in 2025, with total revenue projected at 13.042 billion yuan, a year-on-year increase of 38.4%, and product revenue at 11.896 billion yuan, up 44.6% [1][2] - The company has established significant partnerships with Roche, Takeda, and Eli Lilly, highlighting its strong R&D capabilities and increasing international recognition [1] - The company is becoming a leading pharmaceutical enterprise in China, with a competitive global innovation pipeline, and aims to become a world-class biopharmaceutical company [1] Financial Performance - In 2025, the company reported total revenue of 13.042 billion yuan, a 38.4% increase year-on-year, with product revenue reaching 11.896 billion yuan, up 44.6% [1] - The company achieved a turnaround in IFRS net profit, reporting 814 million yuan in 2025, a significant improvement from a loss of 95 million yuan in 2024, driven by strong revenue growth and improved operational efficiency [1] - Non-IFRS net profit for 2025 was 1.723 billion yuan, a substantial increase from 332 million yuan in 2024, with EBITDA reaching 1.99 billion yuan, up from 412 million yuan in 2024 [1] Commercialization and Product Development - The company has built a leading oncology brand in China and is developing a rising chronic disease innovation brand, with a comprehensive product portfolio and a mature commercialization network [2] - The product portfolio has expanded to 18 products, with 12 included in the national medical insurance, covering oncology, metabolism, and autoimmune diseases [2] - The company’s product revenue of 11.896 billion yuan in 2025 marks its first breakthrough of 10 billion yuan, reflecting the foresight and efficient commercialization execution, with expectations to exceed 20 billion yuan in product revenue by 2027 [2]

Core Viewpoint - The collaboration between the company and Eli Lilly marks another significant licensing deal worth over $8.85 billion, reinforcing the strength of the company's antibody technology platform [1] Group 1: Collaboration Details - The company has entered into a strategic partnership with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology [1] - The agreement includes an upfront payment of $350 million, potential milestone payments of up to $8.5 billion, and a tiered sales revenue sharing structure [1] - The company retains all rights in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside this region [1] Group 2: Financial Projections and Growth - The company anticipates a revenue growth of approximately 45% year-on-year in 2025, reaching around 11.9 billion RMB, with Q4 2025 expected to generate about 3.3 billion RMB [2] - The product pipeline, including IBI363, IBI343, and IBI324, is projected to drive significant revenue growth, with a combined potential market space exceeding $60 billion [2] - Management expects to generate 8-10 new molecules annually from its early-stage clinical pipeline starting in 2026, aiming to push five products into global Phase III trials by 2030 [2] Group 3: Target Price and Ratings - The target price is maintained at HKD 105, reflecting the potential contributions from the Eli Lilly collaboration and adjustments based on the latest management guidance regarding the Takeda collaboration [3]

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly in the collaboration between Innovent Biologics and Eli Lilly, which focuses on new drug development in oncology and immunology, with a deal size exceeding expectations [1] - The collaboration employs a "China PoC + global development" model, leveraging Innovent's efficient clinical validation capabilities in China while utilizing Eli Lilly's global commercialization network to mitigate risks, marking a key step in the globalization of Chinese innovative pharmaceutical companies [1] - The assets involved in the collaboration, such as IBI363 and IBI343, have entered global multi-center Phase III clinical trials, with a combined potential market space of $60 billion [1] Group 2 - The ADC commercialization process is accelerating, with 20 ADC drugs approved globally, six of which have consistently been in the "billion-dollar club" for two years; approximately 60 are in Phase III clinical trials or awaiting market approval [2] - Local companies are increasingly gaining advantages due to their self-commercialization capabilities, as seen with Rongchang Biologics transitioning from outsourcing to in-house production, and Keren Biotechnology and Baillie Tianheng accelerating the establishment of their own production bases [2] - The Hong Kong Innovation Drug ETF has seen a strong performance, with a 3.10% increase as of February 10, 2026, and a total scale of 25.98 billion yuan, indicating a positive trend in investment within the sector [2]

Summary of the Conference Call Company and Industry Involved - **Company**: Innovent Biologics (信达生物) - **Partner**: Eli Lilly (礼来制药) - **Industry**: Biopharmaceuticals, specifically focusing on oncology and immunology Core Points and Arguments - **Strategic Collaboration**: Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology [1] - **Development Responsibilities**: Innovent will lead the projects from drug discovery to clinical proof of concept in China, specifically completing Phase II clinical trials [1] - **Global Rights**: Eli Lilly will obtain exclusive global development and commercialization rights outside Greater China, while Innovent retains all rights within Greater China [1] - **Financial Terms**: Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [1] - **Sales Revenue Sharing**: Innovent is entitled to a tiered sales revenue share from net sales outside Greater China for each product [2] Additional Important Insights - **Seventh Collaboration**: This marks the seventh collaboration between Innovent and Eli Lilly, indicating a strong ongoing relationship [3] - **Risk Mitigation**: The "China PoC + global development" model reduces Innovent's overseas development risks while leveraging Eli Lilly's global network to enhance efficiency [4] - **Strategic Significance**: The collaboration's financial components will strengthen Innovent's financial security, and the sales revenue sharing will provide long-term benefits from global market growth [5] - **Synergy with Existing Pipeline**: The focus on oncology and immunology aligns with Innovent's existing core pipeline, including products like IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC), enhancing overall competitiveness [5] - **Potential Early-Stage Products**: Other early-stage clinical products with significant market potential include IBI324 (VEGF-A/Ang-2), IBI3001 (EGFR/B7H3 ADC), and IBI3002 (IL-4Rα/TSLP) [5]

Core Viewpoint - The recent strategic partnership between Innovent Biologics and Eli Lilly is expected to enhance Innovent's financial stability and competitive position in the oncology and immunology sectors, with significant upfront and milestone payments involved [1][2]. Group 1: Financial Impact - Innovent Biologics has secured an upfront payment of $350 million from Eli Lilly, which will be received shortly and is intended to cover future overseas clinical investments [1]. - The total potential milestone payments could reach approximately $8.5 billion, providing a substantial financial cushion for the company [1]. - The sales sharing arrangement for products outside Greater China is expected to yield long-term benefits as the global market grows [2]. Group 2: Strategic Focus - The collaboration will focus on innovative drug development in oncology and immunology, aligning with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2 ADC) [2]. - This partnership is anticipated to enhance Innovent's overall competitiveness in the market by leveraging synergies with its current product offerings [2]. Group 3: Market Perception - Haitong International views the upfront and milestone payments as a reinforcement of Innovent's financial safety net, while Goldman Sachs believes the current stock price is undervalued, assigning a "Buy" rating with a target price of HKD 102.85 [2].

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

Core Insights - The company achieved total product revenue exceeding 3.3 billion yuan in Q3 2025, reflecting a robust year-on-year growth of approximately 40%, surpassing expectations, driven by oncology and comprehensive pipeline products [1] - The strategic partnership with Takeda, valued at up to 11.4 billion USD, marks a significant step in the company's globalization strategy, with an initial payment of 1.2 billion USD and potential milestone payments [2] Revenue Growth - The core products, including Xinlianli (信迪利单抗), showed steady growth, while products like Masitide (玛仕度肽) and Tolezomab (托莱西单抗) demonstrated significant market access and channel marketing effectiveness, leading to accelerated revenue contributions [1] - The company has received approval for 16 products, with 2 additional products under review, indicating a strong product pipeline [1] Strategic Partnership - The collaboration with Takeda involves three core innovative drugs, including IBI363, IBI343, and IBI3001, with a focus on global development and commercialization [2] - IBI363 is expected to have a market potential exceeding 40 billion USD, with specific segments like second-line lung cancer and first-line colorectal cancer contributing significantly to this figure [2] Financial Projections - The revenue forecast for 2025-2027 has been revised upwards, with expected revenues of 12.787 billion, 22.479 billion, and 20.464 billion yuan, reflecting growth rates of 35.72%, 75.79%, and -8.96% respectively [2] - The projected net profit attributable to the parent company is estimated at 994 million, 7.251 billion, and 3.013 billion yuan for the same period [2]

Investment Rating - The report maintains an "Overweight" rating for several pharmaceutical companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Jiangsu Nhwa Pharmaceutical, with related targets such as CSPC Innovation Pharmaceutical [6][28]. Core Insights - The innovative drug sector is experiencing high prosperity, and the report continues to recommend innovative drugs and their industry chain. It highlights the recent global strategic collaboration between Innovent Biologics and Takeda, which is expected to catalyze the innovative drug market [6][29]. - The report notes that the A-Shares pharmaceutical sector underperformed the market in the fourth week of October 2025, with the SW Pharmaceutical and Biological index rising only 0.6% compared to a 2.9% increase in the SHCOMP [8][30]. - In the same period, the Hong Kong pharmaceutical sector also underperformed, while the U.S. pharmaceutical sector performed in line with the market [31][19]. Summary by Sections Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the ongoing recommendation of innovative drugs and the industry chain, maintaining "Overweight" ratings for various companies including Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, and Nhwa Pharmaceutical. It also recommends Biopharma/Biotech companies with innovative pipelines and increasing performance, maintaining "Overweight" ratings for Innovent Biologics, Xiamen Amoytop Biotech, and others [6][28]. Performance of A-Shares Pharmaceutical Sector - In the fourth week of October 2025, the A-Shares pharmaceutical sector's performance was weaker than the overall market, with a 0.6% increase compared to the SHCOMP's 2.9% rise. The medical service, pharmaceutical commerce, and medical equipment sub-sectors showed relatively better performance [8][30]. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector underperformed the market with a decline of 0.8%, while the U.S. pharmaceutical sector matched the market performance with a 1.9% increase. Notable stock movements included significant gains for companies like WuXi AppTec and declines for Alphamab Oncology in Hong Kong [31][19].